Literature DB >> 31576286

Current landscape of cytoreductive nephrectomy: who, when, and why?

Jiping Zeng1, Alfredo Harb-De la Rosa1, Juan Chipollini1.   

Abstract

Year:  2019        PMID： 31576286      PMCID： PMC6685835          DOI： 10.21037/atm.2019.04.03

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  12 in total

1.  Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.

Authors:  R C Flanigan; S E Salmon; B A Blumenstein; S I Bearman; V Roy; P C McGrath; J R Caton; N Munshi; E D Crawford
Journal:  N Engl J Med       Date:  2001-12-06       Impact factor: 91.245

2.  External validation of a predictive model of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma.

Authors:  Lorenzo Marconi; Roderick de Bruijn; Erik van Werkhoven; Christian Beisland; Kate Fife; Axel Heidenreich; Anil Kapoor; Jose Karam; Caroline Kauffmann; Tobias Klatte; Boerje Ljungberg; Surena Matin; Daniel Sjoberg; Michael Staehler; Grant D Stewart; Simon Tanguay; Robert Uzzo; Sarah Welsh; Lori Wood; Chris Wood; Axel Bex
Journal:  World J Urol       Date:  2018-08-01       Impact factor: 4.226

3.  Comparative Survival following Initial Cytoreductive Nephrectomy versus Initial Targeted Therapy for Metastatic Renal Cell Carcinoma.

Authors:  Bimal Bhindi; Elizabeth B Habermann; Ross J Mason; Brian A Costello; Lance C Pagliaro; R Houston Thompson; Bradley C Leibovich; Stephen A Boorjian
Journal:  J Urol       Date:  2018-03-21       Impact factor: 7.450

4.  Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma.

Authors:  Bimal Bhindi; E Jason Abel; Laurence Albiges; Karim Bensalah; Stephen A Boorjian; Siamak Daneshmand; Jose A Karam; Ross J Mason; Thomas Powles; Axel Bex
Journal:  Eur Urol       Date:  2018-10-25       Impact factor: 20.096

5.  Should CARMENA Really Change our Attitude Towards Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma? A Systematic Review and Meta-Analysis Evaluating Cytoreductive Nephrectomy in the Era of Targeted Therapy.

Authors:  Francesco Massari; Vincenzo Di Nunno; Lidia Gatto; Matteo Santoni; Riccardo Schiavina; Laura Cosmai; Eugenio Brunocilla; Andrea Ardizzoni; Camillo Porta
Journal:  Target Oncol       Date:  2018-12       Impact factor: 4.493

6.  Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial.

Authors:  G H Mickisch; A Garin; H van Poppel; L de Prijck; R Sylvester
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

7.  Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomy.

Authors:  Alexander Kutikov; Robert G Uzzo; Aaron Caraway; Carl T Reese; Brian L Egleston; David Y T Chen; Rosalia Viterbo; Richard E Greenberg; Yu-Ning Wong; Jay D Raman; Stephen A Boorjian
Journal:  BJU Int       Date:  2009-11-17       Impact factor: 5.588

8.  Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma.

Authors:  Arnaud Méjean; Alain Ravaud; Simon Thezenas; Sandra Colas; Jean-Baptiste Beauval; Karim Bensalah; Lionnel Geoffrois; Antoine Thiery-Vuillemin; Luc Cormier; Hervé Lang; Laurent Guy; Gwenaelle Gravis; Frederic Rolland; Claude Linassier; Eric Lechevallier; Christian Beisland; Michael Aitchison; Stephane Oudard; Jean-Jacques Patard; Christine Theodore; Christine Chevreau; Brigitte Laguerre; Jacques Hubert; Marine Gross-Goupil; Jean-Christophe Bernhard; Laurence Albiges; Marc-Olivier Timsit; Thierry Lebret; Bernard Escudier
Journal:  N Engl J Med       Date:  2018-06-03       Impact factor: 91.245

9.  Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial.

Authors:  Axel Bex; Peter Mulders; Michael Jewett; John Wagstaff; Johannes V van Thienen; Christian U Blank; Roland van Velthoven; Maria Del Pilar Laguna; Lori Wood; Harm H E van Melick; Maureen J Aarts; J B Lattouf; Thomas Powles; Igle Jan de Jong Md PhD; Sylvie Rottey; Bertrand Tombal; Sandrine Marreaud; Sandra Collette; Laurence Collette; John Haanen
Journal:  JAMA Oncol       Date:  2019-02-01       Impact factor: 31.777

Review 10.  Surgical Management of Advanced Kidney Cancer: The Role of Cytoreductive Nephrectomy and Lymphadenectomy.

Authors:  Hiten D Patel; Jose A Karam; Mohamad E Allaf
Journal:  J Clin Oncol       Date:  2018-10-29       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.